Ocugen Licenses OCU400 Gene Therapy to Celairis for APAC Expansion
Ocugen partners with Celairis to launch OCU400 gene therapy in Australia, New Zealand, and ASEAN—expanding cartilage‑regeneration markets and boosting investor confidence.
3 minutes to read
